The University of Arizona James E. Rogers College of Law and AZBio have joined forces to offer a 10% tuition discount to AZBio members for all online degrees and programs offered at the college.Continue reading
Monthly Archives: October 2021
Tesis Labs Raises $20 Million in Growth Equity Capital to Expand Clinical Capacity
The funding round bolsters Tesis Labs’ capacity to meet the growing customer demand and clinical research initiativesContinue reading
$3,000 Grants available for SBIR submissions- SBA FAST Program
Arizona’s FAST program funds resources, training and network opportunities to aid entrepreneurs in their SBIR proposal success. Grants will be distributed in three rounds from October 2021 to September 2022. Each round will award six applicants up to $3,000 each.
Francis Collins to step down as director of the National Institutes of Health
Francis S. Collins, M.D., Ph.D., today announced his decision to end his tenure as the director of the National Institutes of Health by the end of the year. Dr. Collins is the longest serving presidentially appointed NIH director, having served three U.S. presidents over more than 12 years.Continue reading
HTG Expands Therapeutics Team
Veteran Drug Developer Stephen Barat, Ph.D. Joins to Head Company’s Therapeutics DivisionContinue reading
SynCardia Systems LLC acquired by Picard Medical, Inc
Tucson, AZ – based SynCardia is the only company in the world with a US FDA-approved temporary Total Artificial Heart (TAH). It is also CE marked in Europe and approved for use in over 30 countries around the world. The SynCardia TAH has been saving and extending lives in Europe and North America, having been implanted over 2,000 times to-date and it has accumulated hundreds of years of proven patient use and safety data.Continue reading
The University of Arizona College of Medicine – Phoenix Partners with the Joy Bus
UArizona Awarded $60 Million to Lead Precision Aging Network
The network, established with funding from the National Institutes of Health, has the the ultimate goal of developing more effective brain-aging treatments and interventions targeted to the individual.
Continue reading
NASA Awards PADT and Penn State University a $375,000 Phase III STTR Research Grant
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died
Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide
If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19Continue reading